Proteinase-activated receptor (PAR) 2 is activated by trypsinlike serine proteinases and has been implicated in intestinal inflammation. However, its role in the regulation of intestinal mucosal function remains unclear. Using the intestinal epithelial cell line, SCBN, we have studied the stimulus-secretion coupling mechanisms of PAR 2 -induced epithelial chloride transport, focusing on cyclooxygenase (COX)-1 and COX-2 activities and prostaglandin (PG) E 2 secretion. SCBN monolayers were grown on Snapwell supports, mounted in modified Ussing chambers, and exposed to the activating peptide, SLIGRL-NH 2 (50 M), to activate PAR 2 . Pretreatment with inhibitors of cytosolic PLA 2 (cPLA 2 ) (AACOCF3, arachidonyltrifluoromethyl ketone), COX-1 [SC560, 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole], and COX-2 (celecoxib) resulted in a significant concentration-dependent attenuation of PAR 2 -induced changes in short-circuit current. Immunoblot analysis showed a PAR 2 -induced increase in cPLA 2 phosphorylation that was blocked by the mitogen-activated protein kinase kinase inhibitor, PD98059 [2-(2-amino-3methoxyphenyl)-4H-1benzopyran-4-one, C 16 H 13 NO 3 ], and the pan-protein kinase C inhibitor, GFX (bisindolylmaleimide). PAR 2 stimulation also resulted in a large increase in the production of PGE 2 as determined by enzyme-linked immunosorbent assay and was also blocked by PD98059 and GFX. Immunofluorescence and immunoblot analysis determined that EP2 and EP4 are expressed at the basolateral membrane of SCBN cells. Through the use of selective inhibitors (EP2, AH6809 [6-isopropoxy-9-oxoxanthene-2-carboxylic acid]; EP4, GW627368X [N-{2[4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl] acetyl}benzene sulphonamide]), it was found that both EP2 and EP4 were involved in mediating the PAR 2 -induced chloride secretory response. We conclude that basolateral PAR 2 activation induces epithelial chloride secretion that is mediated by cPLA 2 , COX-1, COX-2, and the subsequent release of PGE 2 . The production of PGE 2 results in an autocrine secretory response that is dependent on basolateral EP2 and EP4 receptors.
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Proteinase-activated receptors (PARs) are a unique class of G-protein-coupled receptors that are activated by serine protease-mediated cleavage of the N terminus of the receptor (Ossovskaya and Bunnett, 2004) . This cleavage results in a new N terminus that acts as a tethered ligand that can interact with a specific amino acid sequence on extracellular loop 2 of the receptor and result in the initiation of intracellular signaling events. Currently, four PAR receptor subtypes have been described, PAR [1] [2] [3] [4] . PAR 2 can be activated by a number of serine proteinases, including trypsin, mast cell tryptase, kallikreins, and the tissue factor/VIIa/Xa complex Ossovskaya and Bunnett, 2004; Oikonomopoulou et al., 2006) . PAR 2 has a wide distribution throughout the gastrointestinal tract and is expressed on both the apical and basolateral membranes of enterocytes (Nystedt et al., 1994; Bohm et al., 1996) . After intestinal damage or during inflammation, many of these proteinases may be present in close proximity to epithelial PAR 2 and could activate the receptor under these circumstances. It is important that synthetic peptides that correspond to the tethered ligand sequence can be used to activate the receptor in the absence of receptor cleavage. For PAR 2 , these include SLIGRL-NH 2 and 2-furoyl-LIGRLO-NH 2 (Kawabata et al., 2004; McGuire et al., 2004) .
In a previous study, we demonstrated that PAR 2 -induced chloride secretion was dependent upon epidermal growth factor receptor transactivation, MAP kinase (ERK1/2) signaling, calcium, and protein kinase (PK) A (van der Merwe et al., 2008) . It is important that increases in ERK1/2 activity can result in the serine phosphorylation and activation of cPLA 2 , resulting in the liberation of arachidonic acid from membrane phospholipids (Leslie, 2004) . Through the actions of either COX-1 or COX-2 (or both), arachidonic acid is converted to PGH 2 , which is then rapidly metabolized by various PG synthases to form prostaglandins such as PGE 2 (Helliwell et al., 2004) . PGE 2 has long been known to play an important role in intestinal chloride secretory responses (Field et al., 1981) and is considered the final common mediator for a number of secretagogues (Hinterleitner and Powell, 1991) . PGE 2 has four receptor subtypes, EP1 to EP4, all of which are G protein-coupled receptors binding to G␣ q (EP1), G␣ i (EP3), or G␣ s (EP2, EP4). Thus, PGE 2 signaling has important implications in chloride secretory responses because binding to EP receptors can result in increases in both intracellular calcium and cAMP, which are important mediators of epithelial chloride transport (Barrett and Keely, 2000) . In our previous studies, we have demonstrated a potential role for COX activity in PAR 2 -mediated chloride secretion (van der Merwe et al., 2008) . Other reports also have suggested an important role for COX activity in PAR 2 -mediated ion transport (Kong et al., 1997; Green et al., 2000; Palmer et al., 2006) . Furthermore, in lung epithelial cells, it has been demonstrated that PAR 2 activation can stimulate chloride secretion via the release of PGE 2 and PGF 1␣ (Palmer et al., 2006) ; however, the specific role these prostaglandins may have in PAR 2 -mediated intestinal epithelial transport remains unclear. We explored this issue in the chloride-secreting SCBN epithelial cell line and demonstrated that basolateral PAR 2 -induced chloride secretion involves MAP kinase and PKC-dependent activation of cPLA 2 and COX-1-and COX-2-mediated PGE 2 production and signaling via both EP2 and EP4 receptors.
Materials and Methods
Cell Culture. The canine intestinal, epithelial cell line SCBN (Buret and Lin, 2008) was used for the ion transport studies and cultured as we have described previously (Buresi et al., 2002) . SCBN cells between passages 20 and 30 were grown to confluence either in flasks (75 cm 2 ) or on semipermeable Snapwell supports (Corning Life Sciences, Lowell, MA). Cells grown in flasks were passaged using 1.5ϫ trypsin and fed every 2nd day using Dulbecco's modified Eagle's medium supplemented with 5% fetal calf serum, L-glutamine, streptomycin, plasmocin, and tylosin. Similarly, cells grown on either Snapwell or Transwell semipermeable supports were fed every 2nd day, and confluence was determined by a light microscope or an electrovoltohmmeter (EVOM; WPI, Sarasota, FL). Only monolayers having a resistance of Ͼ500 ⍀/cm 2 were used for Ussing chamber experiments.
Ion Transport. SCBN cells were grown to confluence on Snapwell supports and mounted in modified Ussing chambers. The cells were bathed with modified Krebs' buffer (115 mM NaCl, 2.0 mM KH 2 PO 4 , 2.4 mM MgCl 2 , 1.3 mM CaCl 2 , 25.0 mM NaHCO 3 , and 8.0 mM KCl) on both the apical and basolateral sides of the chamber. Krebs' buffer contained 10 mM mannitol on the apical side and 10 mM glucose on the basolateral side. Buffers were maintained at 37°C and pH 7.4 and continuously gassed with 5% CO 2 and 95% O 2 . The transepithelial potential difference was clamped to 0 V using a voltage-clamp apparatus (VCC MC8; Physiologic Instruments, San Diego, CA), and changes in short-circuit current (Isc) were monitored as a reflection of net electrogenic ion transport. The Isc was recorded with a digital data acquisition system (MP100; BIOPAC Systems, Inc., Goleta, CA) and analyzed using AcqKnowledge software (version 3.5.7; BIOPAC Systems, Inc.).
To assess the role of COX-1, COX-2, and cPLA 2 , the cells were incubated with inhibitors of COX-1 (SC560, 1-250 nM), COX-2 (celecoxib, 10 nM-2.5 M), or cPLA 2 (AACOCF3, 30 M). After a 15-min incubation with the respective inhibitor, monolayers were exposed basolaterally to SLIGRL-NH 2 (50 M), and the change in Isc was measured. The vehicle, DMSO (1:1000), was used as a control.
To determine a role for specific EP receptors (EP 2 and EP 4 ) in PAR 2 -induced Isc changes, confluent SCBN monolayers were mounted in Ussing chambers and pretreated for 15 min with the pan-EP receptor inhibitor (EP 1,2 and DP 1 ), AH6809 (25 M), and the EP 4 inhibitor, GW627368X (GWX; 1 M), before basolateral exposure to 50 M SLIGRL-NH 2 . The vehicle, DMSO (1:1000), was used as a control.
Prostaglandin ELISA. The production of PGE 2 and PGF 2␣ after PAR 2 stimulation by SLIGRL-NH 2 (50 M) was assessed using commercially available ELISA kits (Cayman Chemical, Ann Arbor, MI). In brief, SCBN cells were grown to confluence on 24-mm Transwell supports, serum-starved for 2 h, and treated for 15 min with inhibitors of PKC (GFX, 1 M), ERK1/2 activation (the MEK inhibitor, PD98059, 30 M), COX-1 (SC560, 10 nM), and COX-2 (celecoxib, 30 nM) or vehicle. After pretreatment with inhibitor, the cells were exposed basolaterally to 50 M SLIGRL-NH 2 for 5 min, and cell culture media samples from the basolateral compartment were collected for analysis by ELISA for PGE 2 and PGF 2␣ , performed according to the manufacturer's instructions.
Immunoblotting. Immunoblot analysis was conducted to demonstrate the constitutive expression of COX-1, COX-2, EP 2 , and EP 4 in SCBN cells. In addition, to confirm the physiological results obtained with the various pharmacological inhibitors, immunoblot analysis was conducted to determine the activation of cPLA 2 . SCBN cells were grown to confluence in 75-cm 2 flasks, serum-starved for 2 h, and then resuspended in serum-free media. Cells were then exposed to SLIGRL-NH 2 (50 M) or vehicle for 5 min, placed on ice, and rinsed with ice-cold PBS to stop the reaction. Whole-cell lysates were collected, and the proteins were resolved by 4 to 12% gradient SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. After overnight exposure to the primary antibody at 4°C, blots were treated with horseradish peroxidase-conjugated secondary antibody at room temperature for 1 h. Bands were then visualized with enhanced chemiluminescence reagent (ECL; Amersham Pharmacia, Chalfont St. Giles, UK) on a Gel-Doc 1000 (Bio-Rad, Hercules, CA) and quantified by densitometry performed using Quantity One software (Bio-Rad).
To assess the phosphorylation and activation of cPLA 2 , whole-cell lysates were collected after a 5-min exposure to SLIGRL-NH 2 (50 M) or vehicle. In some experiments SCBN cells were pretreated with inhibitors of ERK1/2 activation (the MEK inhibitor, PD98059, 50 M) and PKC (GFX, 1 M) to assess the role these kinases may be playing in PAR 2 -stimulated cPLA 2 phosphorylation. Immunoblots using rabbit polyclonal antibodies (1:2000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) to phospho-cPLA 2 and an HRP-conjugated goat anti-rabbit secondary antibody (1:10,000; Jackson ImmunoResearch Laboratories Inc., West Grove, PA) were conducted. Blotting for total-cPLA 2 (1:2000; Santa Cruz Biotechnology, Inc.) was used as a loading control.
To assess constitutive expression of COX-1, COX-2, EP 2 , and EP 4 in SCBN cells, whole-cell lysates were collected. Immunoblot analysis was conducted using a mouse monoclonal antibody specific to COX-1 (1:200; Cayman Chemical) and an HRP-conjugated goat antimouse secondary antibody (1:5000; Jackson ImmunoResearch Laboratories Inc.). Similarly, for COX-2, immunoblotting was conducted using a mouse monoclonal antibody specific to COX-2 (1:500; Cayman Chemical) and an HRP-conjugated secondary antibody (1:5000; Jackson ImmunoResearch Laboratories Inc.). To determine the base- at ASPET Journals on July 9, 2017 jpet.aspetjournals.org line expression of EP2 and EP4, immunoblotting was conducted using rabbit polyclonal antibodies to EP2 and EP4 (1:500; Cayman Chemical) and an HRP-conjugated secondary antibody (1:5000; Jackson ImmunoResearch Laboratories Inc.).
Immunofluorescence. To substantiate our immunoblotting findings and determine polarity of the EP 2 and EP 4 receptors in SCBN cells, immunofluorescence was conducted as described previously (van der Merwe et al., 2008) . In brief, SCBN cells were grown to confluence on 12-mm Transwell filters and serum-starved for 2 h. The cells were then rinsed with ice-cold PBS and fixed using Ϫ20°C methanol for 30 min. The cells were washed with PBS and blocked with 10% bovine serum albumin for 2 h. The cells were incubated overnight at 4°C with rabbit polyclonal antibodies (1:100, 5% bovine serum albumin, 0.1% Triton X-100) to EP 2 and EP 4 . Expression of these proteins was visualized using a fluorescein isothiocyanateconjugated anti-mouse secondary (occludin) and a Cy3-conjugated anti-rabbit secondary (EP 2 and EP 4 ). The Transwell filters were then removed, mounted on slides, and imaged using an Olympus Fluoview 1000 confocal microscope (Olympus, Tokyo, Japan).
Materials. Dulbecco's modified Eagle's medium, antibiotic solutions, PD153035, and PD98059 were obtained from Sigma-Aldrich (St. Louis, MO). GFX was obtained from Calbiochem (San Diego, CA). Cell dissociation buffer (HyQtase) and fetal bovine serum were obtained from HyClone Laboratories (Logan, UT). Antibodies for cPLA 2 were obtained from Santa Cruz Biotechnology, Inc. Antibodies for EP 2 , EP 4 , COX-1, and COX-2, the ELISA kits for PGE 2 and PGF 2␣ , and SC560 and celecoxib were obtained from Cayman Chemical. The PAR 2 -activating peptide, SLIGRL-NH 2 , was synthesized in house by Dr. Denis McMaster in the University of Calgary Core Peptide Synthesis Service.
Statistical Analysis. Data are expressed as the mean Ϯ S.E.M. Statistical analyses were conducted using GraphPad Instat version 3.0 (GraphPad Software Inc., San Diego, CA). Comparisons of two groups were made using Student's t test for unpaired data. Comparisons of more than two groups were made using a two-way analysis of variance with a post hoc Newman-Keuls test. An associated probability (p value) of 0.05 was considered significant.
Results

COX-1 and COX-2 Expression in SCBN Cells.
To demonstrate whether there was constitutive expression of both COX-1 and COX-2 in SCBN cells, immunoblot analysis of whole-cell lysates was conducted. SCBN cells expressed both COX-1 and COX-2 under basal conditions (Fig. 1) .
PAR 2 Activation of Ion Transport: Roles of COX-1 and COX-2. Basolateral treatment of SCBN cells with 50 M SLIGRL-NH 2 resulted in a transient increase in Isc as described previously (van der Merwe et al., 2008) . Pretreatment of the SCBN cells with inhibitors of COX-1 (SC560) or COX-2 (celecoxib) resulted in a concentration-dependent inhibition of the chloride secretory responses to PAR 2 activation by SLIGRL-NH 2 ( Fig. 2A) . Pretreatment of the cells with higher concentrations of selective antagonists of either COX-1 or COX-2 alone resulted in almost complete inhibition of the response to PAR 2 activation. To determine whether the effects of COX-1 and COX-2 inhibition were additive, experiments were conducted in which concentrations of SC560 (10 nM) and celecoxib (30 nM) that, on their own, caused an inhibition of PAR 2 -induced ⌬Isc of ϳ25%, were added simultaneously. It is interesting that the combination of SC560 and celecoxib did not cause a greater inhibition of PAR 2 -induced secretion than each inhibitor on its own (Fig. 2B) .
PAR 2 Stimulation of cPLA 2 . We assessed whether PAR 2 -induced ⌬Isc was dependent upon the activation of cPLA 2 . Inhibition of cPLA 2 with AACOCF3 (30 M) resulted in a significant reduction in the response to SLIGRL-NH 2 (Fig. 3A) . To further substantiate our Ussing chamber experiments, immunoblot analysis revealed that stimulation of PAR 2 with SLIGRL-NH 2 resulted in an increase in cPLA 2 phosphorylation that was prevented by either the MEK inhibitor, PD98059 (30 M), or the pan-PKC inhibitor, GFX (1 M) (Fig. 2B) . These results suggest that the activation of both PKC and ERK1/2 is required for PAR 2 -induced cPLA 2 phosphorylation and subsequent stimulation of chloride secretion in SCBN cells.
PAR 2 -Induced PG Production. Based on our results demonstrating a role for both COX-1 and COX-2 in PAR 2 -induced chloride secretion in SCBN cells, we sought to determine whether PAR 2 activation could result in the production of secretory prostanoids. Basolateral treatment of SCBN cells with 50 M SLIGRL-NH 2 resulted in a significant increase in PGE 2 production compared with controls (Fig. 4) . Pretreatment of SCBN cells with selective inhibitors of COX-1 (SC560, 10 nM) or COX-2 (celecoxib, 30 nM), concentrations that reduced PAR 2 -induced ⌬Isc by approximately 25%, caused an approximately 75% inhibition in PAR 2 -induced PGE 2 release from SCBN 2 . Role of COX-1 and COX-2 in PAR 2 -induced chloride secretion. A, PAR 2 activation by 50 M SLIGRL-NH 2 induces chloride secretion dependent upon both COX-1 (inhibited in a concentration-dependent manner by pretreatment with SC560) and COX-2 (inhibited in a concentration-dependent manner by celecoxib). ‫,ء‬ p Ͻ 0.05; ‫,ءءء‬ p Ͻ 0.001; n Ն 6. B, SCBN monolayers were pretreated with the COX-1 inhibitor, SC560 (10 nM), the COX-2 inhibitor, celecoxib (30 nM), or a combination of these two inhibitors at the same concentrations as used independently. PAR 2 was then activated, and the ⌬Isc was measured. ‫,ء‬ p Ͻ 0.05, n Ն 8.
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at ASPET Journals on July 9, 2017 jpet.aspetjournals.org Downloaded from monolayers (Fig. 4A) . As we saw in the ion transport experiments, the combination of SC560 (10 nM) and celecoxib (30 nM) did not cause an inhibition of PAR 2 -induced PGE 2 synthesis that was greater than that caused by either inhibitor on its own (Fig. 4A) . To further determine the mechanism underlying PAR 2 -induced PGE 2 synthesis in SCBN cells, experiments were conducted in cells pretreated with the MEK inhibitor, PD98059, or the pan-PKC inhibitor, GFX. As we observed in ion transport experiments, these inhibitors both significantly reduced PGE 2 production (Fig. 4B ).
EP2 and EP4 Expression and PAR 2 -Induced Ion
Transport. To determine the expression and cellular distribution of PGE 2 receptors in SCBN cells, immunoblotting and immunofluorescence were conducted for both EP2 and EP4. Western blot analysis revealed that SCBN cells express both EP2 and EP4 under baseline conditions (Fig. 5A) . Furthermore, immunofluorescence demonstrated that EP2 and EP4 were expressed on both the apical and basolateral membranes, although the distribution appeared to be predominantly basolateral (Fig. 5B) . To determine the potential role for these receptor subtypes in PAR 2 -induced chloride secretory responses, SCBN cells were pretreated with inhibitors of EP2 (AH6809) or EP4 (GWX), and responses to 50 M SLIGRL-NH 2 were examined in Ussing chambers. Pretreatment of SCBN cells with inhibitors of either EP2 or EP4 significantly attenuated the chloride secretory response to at ASPET Journals on July 9, 2017 jpet.aspetjournals.org PAR 2 activation, suggesting an important physiological role for both of these receptors in PAR 2 -induced secretion (Fig. 6 ).
Discussion
PAR 2 is expressed on both the apical and basolateral membranes of enterocytes , suggesting an important role in intestinal epithelial cell function. Our studies (van der Merwe et al., 2008) and those of others (Green et al., 2000; Mall et al., 2002) have demonstrated that PAR 2 activation in the intestinal epithelium can result in chloride secretion. We previously demonstrated that PAR 2 -induced chloride secretion is dependent upon Src-mediated epidermal growth factor receptor transactivation, PKC signaling, and subsequent ERK1/2 activation (van der Merwe et al., 2008) , but the actual secretagogue stimulating chloride transport remained unknown. Preliminary findings from that study also suggested a key role for cyclooxygenase activity because the response was reduced by the nonselective COX inhibitor, indomethacin (van der Merwe et al., 2008) . The present study provides insight into roles that COX-1, COX-2, and PGE 2 production play in mediating PAR 2 -stimulated chloride secretion in intestinal epithelial cells. To be specific, we have shown that the stimulation of chloride secretion induced by activation of basolateral PAR 2 in intestinal epithelial monolayers is mediated by a PKC-and ERK1/2-dependent activation of cPLA 2 . This leads to the subsequent COX-1-and COX-2-dependent production of PGE 2 and stimulation of EP2 and EP4 receptors. A schematic diagram of the proposed pathway is presented in Fig. 7 .
We chose the SCBN cell line for our studies because these cells form electrically tight monolayers capable of apically directed chloride transport (Buresi et al., 2002; van der Merwe et al., 2008) . We showed that basolateral PAR 2 activation by SLIGRL-NH 2 resulted in a chloride secretory response that was dependent upon cPLA 2 . We further demonstrated that upon PAR 2 stimulation, there is an increase in phosphorylation and, hence, activation of cPLA 2 , further demonstrating its role in PAR 2 -induced signaling events in these cells. A previous study from our laboratory demonstrated an important role for cPLA 2 in PAR 1 -mediated ion transport (Buresi et al., 2002) . The three main types of phospholipase A include secreted PLA 2 , calcium-independent PLA 2 , and cPLA 2 . The regulation of cPLA 2 involves both Ser phosphorylation and increases in intracellular calcium. ERK1/2 can phosphorylate the catalytic domain of cPLA 2 at Ser505, resulting in an increase in membrane binding and catalytic activity (Lin et al., 1993; Das et al., 2003) . Another important step in the activation of cPLA 2 involves calcium binding to the N-terminal C2 domain, resulting in its translocation to the membrane (Evans et al., 2001) , where it can then catalyze the release of arachidonic acid from membrane phospholipids. Arachidonic acid is then metabolized by COX-1, COX-2, or both to the short-lived PGH 2 , which is enzymatically converted to the various prostanoids, including PGE 2 . We found that under baseline conditions, both COX-1 and COX-2 are expressed constitutively in SCBN cells, suggesting that both of these enzymes may be involved in the ion transport response to PAR 2 activation.
We demonstrated that basolateral activation of PAR 2 resulted in a chloride secretory response that was dependent upon both COX-1 and COX-2. Both the COX-1 inhibitor, SC560, and the COX-2 inhibitor, celecoxib, caused a concentration-dependent inhibition of the PAR 2 -induced change in Isc. It is interesting that a combination of these inhibitors, at concentrations that when applied individually caused a 25% reduction in response to PAR 2 activation, did not have an additive inhibitory effect. We cannot completely discount the possibility that this is due to nonselectivity of the inhibitors, although the concentrations used were well below the published IC 50 values (Warner et al., 1999) . It may be that PAR 2 -mediated ion transport requires the cooperativity of both COX-1 and COX-2, as we have observed in bradykinin-induced ion transport in mouse colon in vitro (MacNaughton and Cushing, 2000) . The potential for, and mechanism of, cooperativity between COX-1 and COX-2 in mediating PAR 2 -evoked ion transport responses will require further investigation.
We demonstrated that PAR 2 activation by SLIGRL-NH 2 results in significant increases in PGE 2 from SCBN cells. PGE 2 stimulates ion transport by the intestinal epithelium (Field et al., 1981; Diener et al., 1988) . There are a number of possible upstream signaling effectors that may regulate PGE 2 production. We demonstrated that PAR 2 -induced PGE 2 production involves COX-1, COX-2, ERK1/2, and PKC. These results, including the observation that COX-1 and COX-2 inhibitors did not have an additive effect on PGE 2 synthesis, paralleled their effects on changes in Isc.
The signaling mechanisms that couple PAR 2 activation with Merwe et al., 2008) . We have now demonstrated an important role for ERK1/2 signaling in the PAR 2 -induced activation of cPLA 2 and production of PGE 2 because these responses were blocked by inhibitors of ERK activation. In addition, we have provided evidence for a role for PKC in PAR 2 -induced changes in short-circuit current. PKC is an important signaling molecule in PAR 2 -mediated ion transport responses and is required for the stimulation of ERK1/2 activity after PAR 2 activation in SCBN cells (van der Merwe et al., 2008) . In that study, a pan-PKC inhibitor, GFX, reduced PAR 2 -induced changes in Isc. In the present study, we have shown that this effect may be due inhibition of PGE 2 synthesis because GFX blocked the PAR 2 -induced production of PGE 2 . Other studies have demonstrated that PKC can potentially stimulate cPLA 2 activity in the absence of ERK1/2 signaling (Xing et al., 1997; Li et al., 2007) . However, our data suggest that ERK1/2 and PKC are part of the same pathway regulating PAR 2 -induced cPLA 2 activation and PGE 2 synthesis because the inhibition of each completely blocked the response. PGE 2 elicits cellular responses by binding to the G proteincoupled EP receptors. Four EP receptor subtypes have been described, EP1 to EP4. EP1 couples G␣ q ; hence, its activation results in calcium increases within the cell (Sugimoto and Narumiya, 2007) . EP2 and EP4 couple to G ␣s and result in cAMP increases within the cell (Sugimoto and Narumiya, 2007) . EP3 signaling is complex because different splice variants can couple to different G proteins (Breyer et al., 1994) . It has been observed that EP3 coupling to G␣ 1 can result in the dampening of EP2/EP4 responses within the cell (Sugimoto and Narumiya, 2007) . In SCBN cells, we demonstrated the expression of both EP2 and EP4, with baseline levels of EP4 greater than those of EP2. Using pharmacological antagonists, we demonstrated that PAR 2 -induced PGE 2 synthesis was dependent on both EP2 and EP4. It should be noted that the antagonist for EP2, AH6809, has been demonstrated to act on EP1 and DP1 (Keery and Lumley, 1988; Woodward et al., 1995) , both of which can stimulate an increase in intracellular calcium and, therefore, could potentially affect chloride secretory responses. Thus, we sought to determine the level of expression of both EP1 and DP1 within SCBN cells. However, immunoblotting did not conclusively determine their expression in SCBN cells (data not shown). Thus, it is likely that PAR 2 -induced PGE 2 production mediates a chloride secretory response dependent upon the activation of EP4 and possibly EP2. This would result in the activation of adenylyl cyclase and, hence, an elevation in intracellular cAMP. We have demonstrated previously that the PAR 2 -induced chloride secretory response is dependent on both cAMP/PKA signaling and CFTR (van der Merwe et al., 2008) . Thus, PAR 2 activation probably stimulates chloride secretion through PGE 2 -and EP2/4-stimulated cAMP/PKA signaling to phosphorylate and activate CFTR.
